Top analyst singles out AMD, Eli Lilly, and Constellation Brands as standout choices for this week's investments

===================================================

In the world of finance, several notable changes have occurred in the stock market this week. Here's a roundup of some of the most significant developments.

Technology Sector

Advanced Micro Devices (AMD) received a positive boost as Truist Securities upgraded the company's stock from Hold to Buy. The investment firm also raised its price target on AMD to $213 from $173. Interestingly, some AI hyperscale customers are reportedly considering a switch from Nvidia (NVDA) to AMD for processing power.

Meanwhile, Citi initiated coverage on Lumentum Holdings (NASDAQ:LITE) with a Buy rating.

Pharmaceutical Sector

Eli Lilly (NYSE:LLY) received a mixed bag of news this week. HSBC upgraded the company's stock to Hold from Reduce, citing the success of its once-daily weight loss pill orforglipron in a Phase 3 trial. However, BofA Securities downgraded Constellation Brands (NYSE:STZ) due to concerns about the potential for further downside in the beer industry, as consumption remains soft.

On a positive note, BofA Securities upgraded Vir Biotechnology (NASDAQ:VIR) to Buy from Neutral, largely due to the promising results of its phase 3 combination drug for a severe liver disease caused by Hepatitis delta virus.

Retail Sector

American Eagle Outfitters (AEO) faced a double whammy this week. BofA downgraded the company's stock from Neutral to Underperform, citing concerns about the namesake brand and its sub-brand Aerie navigating tariffs. The investment bank also assigned a PT of $10 on the stock.

Market Indices

The Dow Jones Industrial Average (DJI) rose 0.6% for the week, while the S&P500 (SP500) closed in the red on Friday. On the other hand, the Nasdaq (COMP:IND) gained marginally for the week.

Scotiabank upgraded Prologis (NYSE:PLD) to Sector Perform from Sector Underperform, based on positive takeaways from the company's second-quarter results, minimal downside risk to earnings estimates, and a fairly priced valuation.

The success of orforglipron was compared favorably to Novo Nordisk's oral diabetes medication Rybelsus in a head-to-head analysis. However, BofA believes American Eagle Outfitters is a long way from its earnings normalizing in the current environment.

This roundup provides a snapshot of the latest developments in the stock market. As always, it's crucial to conduct thorough research before making investment decisions.